Nanobiotix (NBTX) Accounts Payables (2019 - 2025)

Nanobiotix's Accounts Payables history runs 7 years deep, the most recent figure standing at $10.6 million for Q4 2025.

• On a quarterly basis, Accounts Payables fell 50.41% year-over-year to $10.6 million in Q4 2025; TTM through Dec 2025 was $10.6 million, a 50.41% decrease from a year earlier, with the FY2025 full-year figure at $10.3 million, down 51.87% from the prior year.
• Accounts Payables slipped to $10.6 million in Q4 2025 per NBTX's latest filing, from $13.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $21.4 million in Q4 2024 and bottomed at $7.4 million in Q4 2021.
• The 5-year median for Accounts Payables is $11.9 million (2025), against an average of $14.1 million.
• Across the five-year window, Accounts Payables soared 99.9% in 2023 and sank 50.41% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $7.4 million in 2021, then jumped by 32.37% to $9.8 million in 2022, then jumped by 99.9% to $19.6 million in 2023, then rose by 9.11% to $21.4 million in 2024, then sank by 50.41% to $10.6 million in 2025.
• Per Business Quant, the three latest NBTX Accounts Payables figures stand at $10.6 million (Q4 2025), $13.2 million (Q2 2025), and $21.4 million (Q4 2024).